Clinical trial
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
NCT00032799 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00032799 |
|---|---|
| Title | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease |
| Official title | A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | natalizumab |
| Enrollment | 905 |
| Start date | Dec 1, 2001 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Apr 4, 2002 |
| Last update posted | Jun 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: